[go: up one dir, main page]

NI201500135A - Composición farmacéutica de hidrocloruro de s-ketamina - Google Patents

Composición farmacéutica de hidrocloruro de s-ketamina

Info

Publication number
NI201500135A
NI201500135A NI201500135A NI201500135A NI201500135A NI 201500135 A NI201500135 A NI 201500135A NI 201500135 A NI201500135 A NI 201500135A NI 201500135 A NI201500135 A NI 201500135A NI 201500135 A NI201500135 A NI 201500135A
Authority
NI
Nicaragua
Prior art keywords
pharmaceutical composition
ketamine hydrochloride
formulation
ketamine
hydrochloride
Prior art date
Application number
NI201500135A
Other languages
English (en)
Inventor
D G Basstanie Esther
Bentz Johanna
C A Embrechts Roger
Rudolph Niemeijer Nico
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=50687638&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NI201500135(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of NI201500135A publication Critical patent/NI201500135A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/136—Amines having aromatic rings, e.g. ketamine, nortriptyline having the amino group directly attached to the aromatic ring, e.g. benzeneamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/28—Steroids, e.g. cholesterol, bile acids or glycyrrhetinic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Otolaryngology (AREA)
  • Inorganic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Emergency Medicine (AREA)

Abstract

La presente invención se refiere a una formulación acuosa de hidrocloruro de S-ketamina, preferiblemente para la administración nasal, en donde la formulación no contiene ningún conservante antimicrobiano.
NI201500135A 2013-03-15 2015-09-11 Composición farmacéutica de hidrocloruro de s-ketamina NI201500135A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201361791237P 2013-03-15 2013-03-15

Publications (1)

Publication Number Publication Date
NI201500135A true NI201500135A (es) 2016-03-16

Family

ID=50687638

Family Applications (1)

Application Number Title Priority Date Filing Date
NI201500135A NI201500135A (es) 2013-03-15 2015-09-11 Composición farmacéutica de hidrocloruro de s-ketamina

Country Status (16)

Country Link
US (6) US20140274981A1 (es)
EP (2) EP2968122B1 (es)
KR (1) KR102217616B1 (es)
CN (2) CN105073096A (es)
AU (2) AU2014240102A1 (es)
BR (1) BR112015022972B1 (es)
CL (1) CL2015002736A1 (es)
CR (1) CR20150481A (es)
ES (2) ES2755809T3 (es)
MX (1) MX371392B (es)
MY (1) MY180526A (es)
NI (1) NI201500135A (es)
PE (1) PE20200404A1 (es)
PH (1) PH12015502013B1 (es)
SG (2) SG10201802104QA (es)
WO (1) WO2014152196A1 (es)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2897453T3 (es) 2013-09-13 2022-03-01 Univ Chiba Nat Univ Corp Aplicación de R-ketamina y sal de la misma como productos farmacéuticos
US20160332962A1 (en) 2015-05-13 2016-11-17 Janssen Pharmaceutica Nv (s)-csa salt of s-ketamine, (r)-csa salt of s-ketamine and processes for the preparation of s-ketamine
US11191734B2 (en) 2015-06-27 2021-12-07 Shenox Pharmaceuticals, Llc Ketamine transdermal delivery system
CN106562952B (zh) * 2015-10-09 2020-06-09 江阴安博生物医药有限公司 氯胺酮在治疗重性抑郁障碍中的应用
WO2017139382A1 (en) * 2016-02-08 2017-08-17 The Texas A&M University System Combination of adjuvant drugs esketamine and brimonidine for medical treatments
US20180177744A1 (en) * 2016-12-22 2018-06-28 Gary Jay Method of treating pain and depression using a hybrid mixture of s-ketamine and r-ketamine
WO2018234568A2 (en) * 2017-06-23 2018-12-27 Develco Pharma Schweiz Ag Hydroxynorketamine for the use in the treatment of depression
US20200009081A1 (en) 2017-09-13 2020-01-09 Janssen Pharmaceutica N.V. Delivery Of Esketamine For The Treatment Of Depression
PT3505157T (pt) 2017-12-29 2022-02-18 Celon Pharma Sa Composição de cetamina em pó seco para administração pulmonar em depressão resistente ao tratamento
CN111936127A (zh) 2018-02-15 2020-11-13 国立大学法人千叶大学 炎症性疾病或骨病的预防或治疗剂及医药组合物
JP2021523228A (ja) 2018-05-04 2021-09-02 パーセプション ニューロサイエンス，インコーポレイティド 物質乱用の治療方法
US11154537B2 (en) 2018-08-10 2021-10-26 Eleusis Therapeutics Us, Inc. Method of treatment for ketamine infusion
PL3628313T3 (pl) 2018-09-28 2025-06-23 Novohale Therapeutics, Llc Kompozycja ketaminy do zastosowania w sposobie leczenia depresji przez podawanie dopłucne
AU2020231172A1 (en) 2019-03-05 2021-09-23 Janssen Pharmaceuticals, Inc. Esketamine for the treatment of depression
US20220218627A1 (en) 2019-05-31 2022-07-14 Lionheart Pharmaceuticals Aps Intranasal administration of ketamine to cluster headache patients
PL3976145T3 (pl) 2019-05-31 2025-04-28 Celon Pharma S.A. Inhalator do elektronicznie nadzorowanego pozajelitowego podawania kompozycji farmaceutycznej
EP3977469A1 (en) 2019-05-31 2022-04-06 Celon Pharma S.A. Electronically supervised administration of a pharmaceutical composition
TW202135787A (zh) 2019-12-12 2021-10-01 比利時商健生藥品公司 艾氯胺酮調配物及製備與儲存的方法
CN114306218B (zh) * 2020-09-30 2023-11-10 四川普锐特药业有限公司 满足药学抑菌要求的经粘膜给药r-氯胺酮药物组合物
CN113813250B (zh) * 2021-07-21 2023-05-05 广州新济药业科技有限公司 含氯胺酮的药物组合物及其制备方法和应用
JP2025513273A (ja) * 2022-04-26 2025-04-24 イーチャン・ヒューマンウェル・ファーマシューティカル・カンパニー・リミテッド エスケタミン液体製剤及びその使用
EP4480473A4 (en) * 2022-04-26 2025-06-04 Yichang Humanwell Pharmaceutical Co., Ltd. LIQUID ESKETAMINE PREPARATION AND USE THEREOF
WO2024201274A1 (en) 2023-03-24 2024-10-03 Janssen Pharmaceutica Nv Esketamine for use in the treatment of depression
WO2025099181A1 (en) 2023-11-07 2025-05-15 HMNC Holding GmbH Maintenance regime for the administration of 2-(2-chlorphenyl)-2-(methylamino) cyclohexan-1-one

Family Cites Families (72)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH535201A (de) 1969-12-19 1973-03-31 Bristol Myers Co Verfahren zur Spaltung von racemischen 2-(o-Chlorphenyl)-2-methylaminocyclohexanon in die optisch-aktiven Isomeren
JPS632932A (ja) * 1986-06-23 1988-01-07 Teijin Ltd 経鼻投与用粉末状組成物
US5002935A (en) 1987-12-30 1991-03-26 University Of Florida Improvements in redox systems for brain-targeted drug delivery
US4994467A (en) 1989-05-31 1991-02-19 Zimmerman Andrew W Treating autism and other developmental disorders in children with NMDA receptor antagonists
DE4312016A1 (de) * 1993-04-13 1994-10-20 Goedecke Ag Stabile Ketamin-Lösungen
US5543434A (en) 1994-02-25 1996-08-06 Weg; Stuart L. Nasal administration of ketamine to manage pain
ES2205018T3 (es) 1995-02-24 2004-05-01 Stuart Weg Administracion de ketamina para destoxificacion.
WO1997007750A1 (en) 1995-08-30 1997-03-06 Weg Stuart L Administration of ketamine to manage pain and to reduce drug dependency
FR2739294B1 (fr) 1995-09-29 1998-01-16 Lhd Lab Hygiene Dietetique Embout nasal de securite
DE19619665C2 (de) 1996-05-15 2001-03-08 Goedecke Ag Racemattrennung von Ketamin
DE19723133A1 (de) 1997-06-03 1998-12-10 Caideil M P Teoranta Tourmakea Austragvorrichtung für Medien
FR2764807B1 (fr) 1997-06-18 1999-08-20 Valois Sa Dispositif de distribution nasale d'un produit fluide ou pulverulent
JP4790123B2 (ja) * 1998-07-24 2011-10-12 ヨー、セオ、ホン 胆汁酸を有する透明水溶液型製剤の調剤
US6599883B1 (en) 1998-10-30 2003-07-29 Nastech Pharmaceutical Company, Inc. Nasal delivery of xylitol
US6176242B1 (en) 1999-04-30 2001-01-23 Medtronic Inc Method of treating manic depression by brain infusion
US6017961A (en) 1999-07-08 2000-01-25 Flores; John Anthony Ketamine and n-butyl-p-aminobezoate in PLO
EP1103256A1 (de) 1999-11-26 2001-05-30 Claudius Dr. med. Böck Verwendung von Ketamin zur Behandlung von neuroendokriner Immundysfunktion und algogenem Psychosyndrom
US6572849B2 (en) 2000-09-20 2003-06-03 Lee Shahinian, Jr. Self-preserved antibacterial nasal, inhalable, and topical ophthalmic preparations and medications
US6881731B1 (en) 2000-10-23 2005-04-19 Shanbrom Technologies, Llc Enhancers for microbiological disinfection
CA2529857A1 (en) 2002-07-30 2004-02-05 Peter Migaly Combination therapy for depression, prevention of suicide, and varous medical and psychiatric conditions
US7273889B2 (en) 2002-09-25 2007-09-25 Innovative Drug Delivery Systems, Inc. NMDA receptor antagonist formulation with reduced neurotoxicity
NZ540282A (en) 2002-11-18 2008-06-30 Yaupon Therapeutics Inc Analgesic uses of norketamine and ketamine/norketamine prodrugs
US7687080B2 (en) 2002-11-25 2010-03-30 Taraxos Inc. Treatment of neuropathy
US20040214215A1 (en) * 2003-03-07 2004-10-28 Yu Ruey J. Bioavailability and improved delivery of alkaline pharmaceutical drugs
US8082173B2 (en) 2003-05-22 2011-12-20 Cecil Kost Drug sample fulfillment architecture
US20050095277A1 (en) 2003-06-25 2005-05-05 Binnur Ozturk Neuropathy cream
US20040265364A1 (en) 2003-06-25 2004-12-30 Binnur Ozturk Neuropathy cream
US20060223788A1 (en) 2005-03-29 2006-10-05 Cathcart Clifton H Analgesic composition for topical use
EP1885414B1 (en) 2005-06-01 2012-11-21 SHL Group AB Device for delivering medicament
US20060276550A1 (en) 2005-06-03 2006-12-07 Dileep Bhagwat Topical compositions of ketamine and butamben and methods of their use
AU2007229866A1 (en) * 2006-03-22 2007-10-04 Mount Sinai School Of Medicine Intranasal administration of ketamine to treat depression
WO2007123945A2 (en) 2006-04-21 2007-11-01 Aradigm Corporation Mechanical single dose intrapulmonary drug delivery devices
RU2008150624A (ru) 2006-05-22 2010-06-27 Ванда Фармасьютиклз, Инк. (Us) Лечение депрессивных расстройств
DE102007009888A1 (de) * 2007-02-28 2008-09-04 Hermann, Holger Lars, Dr. Verwendung von S-(+)-Ketamin zur Behandlung von Depressionen
US7745665B2 (en) 2007-06-04 2010-06-29 Auspex Pharmaceuticals, Inc. Substituted phenethylamines
US8710070B2 (en) 2008-03-27 2014-04-29 University Of Kentucky Research Foundation Opioid-ketamine and norketamine codrug combinations for pain management
WO2009140269A2 (en) * 2008-05-13 2009-11-19 Clarassance, Inc. Recombinant human cc10 and compositions thereof for use in the treatment of nasal rhinitis
US20110038807A1 (en) 2009-08-14 2011-02-17 Demitri Papolos Compositions and methods for treating bipolar disorder
US20120225949A1 (en) 2009-08-14 2012-09-06 Demitri Papalos Compositions and methods for treating bipolar disorder
KR101831616B1 (ko) 2010-06-15 2018-04-04 그뤼넨탈 게엠베하 통증 치료용 약제학적 병용물
WO2013003669A2 (en) 2011-06-30 2013-01-03 University Of South Florida Compositions, methods of use, and methods of treatment
EP3904332B1 (en) 2011-10-14 2024-12-04 The United States of America, as represented by The Secretary, Department of Health and Human Services The use of (2r, 6r)-hydroxynorketamine, (s)-dehydronorketamine and other stereoisomeric dehydro and hydroxylated metabolites of (r,s)- ketamine in the treatment of depression and neuropathic pain
CA2855640C (en) 2011-11-14 2020-03-10 The General Hospital Corporation Assays and methods for selecting a treatment regimen for a subject with depression
US20130209585A1 (en) 2012-02-13 2013-08-15 Stanley Kim Topical NMDA Antagonist Formulations for the Treatment of Peripheral Neuropathy
US20130236573A1 (en) 2012-03-12 2013-09-12 Janssen Pharmaceutica Nv Esketamine for the treatment of treatment-refractory or treatment-resistant depression
AU2016203771A1 (en) 2012-03-13 2016-06-23 Janssen Pharmaceutica Nv Esketamine for the treatment of treatment-refractory or treatment-resistant depression
WO2013149102A1 (en) 2012-03-30 2013-10-03 The General Hospital Corporation Compositions comprising scopolamine and ketamine in the treatment of depression
WO2014020155A1 (en) 2012-08-02 2014-02-06 Clinpharm Reform Gmbh Oral transmucosal adminstration forms of s-ketamine
EP2887930A4 (en) 2012-08-23 2016-03-23 Stuart L Weg ANXIOLYTIC COMPOSITION, FORMULATION AND METHOD OF USE
FR2994844B1 (fr) 2012-08-31 2015-01-02 Assist Publ Hopitaux De Paris Formulation gelifiante a base de ketamine
NZ619257A (en) 2012-10-08 2015-07-31 Auckland Uniservices Ltd Ketamine derivatives
ES2484068B1 (es) 2013-02-08 2015-04-16 Ana MÍNGUEZ MARTÍ Una composición farmacéutica que contiene ketamina y amitriptilina
EP2983787B1 (en) 2013-04-12 2019-10-02 Icahn School of Medicine at Mount Sinai Method for treating post-traumatic stress disorder
US9913803B2 (en) 2013-08-26 2018-03-13 Amorsa Therapeutics, Inc. Single-layer oral dose of neuro-attenuating ketamine
ES2897453T3 (es) 2013-09-13 2022-03-01 Univ Chiba Nat Univ Corp Aplicación de R-ketamina y sal de la misma como productos farmacéuticos
US9569220B2 (en) 2013-10-06 2017-02-14 Synopsys, Inc. Processor branch cache with secondary branches
CN103705909A (zh) 2013-12-16 2014-04-09 陈镜伊 一种无痛人流用药
WO2015101693A1 (es) 2013-12-31 2015-07-09 Servicio Andaluz De Salud Composiciones y preparaciones combinadas para el tratamiento de las algias orofaríngeas
WO2015108985A1 (en) 2014-01-14 2015-07-23 Children's Hospital Medical Center Compositions comprising ketamine for treating an autism spectrum disorder
DK3131533T3 (da) 2014-04-17 2019-09-16 Develco Pharma Schweiz Ag Oral doseringsform for ketamin
MX2016013787A (es) 2014-05-04 2017-07-24 Firmenich & Cie Productos alimenticios y bebidas que estan saborizados.
FR3023188B1 (fr) 2014-07-04 2016-08-19 Aptar France Sas Dispositif de distribution de produit fluide.
EP3179993B1 (en) 2014-08-13 2021-01-20 Janssen Pharmaceutica NV Esketamine for use in a method for the treatment of depression
CA2961208A1 (en) 2014-09-15 2016-03-24 Janssen Pharmaceutica Nv Val66met (snp rs6265) genotype specific dosing regimens and methods for the treatment of depression
US20180015054A1 (en) 2014-12-31 2018-01-18 Icahn School Of Medicine At Mount Sinai Method of Maintaining the Anti-Depressant Effect of Ketamine With Lithium
CN104798728A (zh) 2015-05-08 2015-07-29 南京中医药大学 产后抑郁动物模型的建立方法及其应用
US20160332962A1 (en) 2015-05-13 2016-11-17 Janssen Pharmaceutica Nv (s)-csa salt of s-ketamine, (r)-csa salt of s-ketamine and processes for the preparation of s-ketamine
US20160338977A1 (en) 2015-05-20 2016-11-24 Janssen Pharmaceutica Nv Methods and kits for treating depression
US11191734B2 (en) 2015-06-27 2021-12-07 Shenox Pharmaceuticals, Llc Ketamine transdermal delivery system
US20180296478A1 (en) 2016-02-12 2018-10-18 Synergistic Therapeutics, Llc Sublingual antidepressant and antianxiety tablet
US20180042936A1 (en) 2016-03-18 2018-02-15 Genomind, Inc. Maintenance therapy using tianeptine
BR112020012473A2 (pt) 2017-12-22 2020-11-24 Janssen Pharmaceuticals, Inc. escetamina para o tratamento da depressão

Also Published As

Publication number Publication date
KR102217616B1 (ko) 2021-02-19
US20250170075A1 (en) 2025-05-29
EP2968122B1 (en) 2019-08-28
KR20150132381A (ko) 2015-11-25
AU2019200424A1 (en) 2019-02-14
PH12015502013A1 (en) 2016-01-11
AU2019200424B2 (en) 2020-05-14
US20230241009A1 (en) 2023-08-03
CN105073096A (zh) 2015-11-18
SG10201802104QA (en) 2018-05-30
EP2968122A1 (en) 2016-01-20
EP3636251B1 (en) 2022-01-19
PH12015502013B1 (en) 2016-01-11
WO2014152196A1 (en) 2014-09-25
CN111643449A (zh) 2020-09-11
EP3636251A1 (en) 2020-04-15
AU2019200424A8 (en) 2019-02-21
US20140274981A1 (en) 2014-09-18
BR112015022972A2 (pt) 2017-07-18
ES2911466T3 (es) 2022-05-19
CR20150481A (es) 2015-10-26
AU2014240102A1 (en) 2015-09-17
ES2755809T3 (es) 2020-04-23
US20190117591A1 (en) 2019-04-25
US11446260B2 (en) 2022-09-20
CL2015002736A1 (es) 2016-03-28
MY180526A (en) 2020-12-01
MX371392B (es) 2020-01-28
US20140275278A1 (en) 2014-09-18
US20200069612A1 (en) 2020-03-05
BR112015022972B1 (pt) 2023-02-14
MX2015012617A (es) 2016-06-21
PE20200404A1 (es) 2020-02-26
SG11201507347QA (en) 2015-10-29

Similar Documents

Publication Publication Date Title
NI201500135A (es) Composición farmacéutica de hidrocloruro de s-ketamina
CY1121928T1 (el) Φαρμακευτικη συνθεση υδροχλωρικης s-κεταμινης
MX2016016666A (es) Derivados de acido boronico y usos terapeuticos de los mismos.
MX2015008627A (es) Derivados de acido boronico y usos terapeuticos de los mismos.
MX2016015093A (es) Derivados de acido boronico y sus usos terapeuticos.
LT3003268T (lt) Stabilūs peroraliniai tirpalai, skirti kompleksiniam aktyviam farmaciniam ingredientui (api)
MX2016005395A (es) Formulacion estable de insulina glulisina.
CO2017007316A2 (es) Formulación farmacéutica
DK3103453T3 (da) Medicinsk sammensætning omfattende heterocyklisk diamino-carboxamidforbindelse som aktiv bestanddel
MX2016001138A (es) Compuestos de benzoxaborol triciclico, metodo de preparacion y uso del mismo.
MX2016001422A (es) Composicion farmaceutica de fingolimod.
EA201491517A1 (ru) N-этил-n-фенил-1,2-дигидро-4,5-дигидрокси-1-метил-2-оксо-3-хинолинкарбоксамид, его получение и применения
HK1212978A1 (zh) 芥子酸的新型衍生物
CL2015003460A1 (es) Composiciones oftálmicas acuosas tópicas que contienen un derivado de 1h-indol-1-carboxamida y uso de estas para el tratamiento de una enfermedad oftálmica
KR101501876B9 (ko) 자일리톨을 유효성분으로 함유하는 인플루엔자 바이러스 감염증 예방 또는 치료용 조성물
EA201890477A1 (ru) Инкапсулированная композиция финголимода
EA201501130A1 (ru) Офтальмологическая фармацевтическая композиция
EA201891848A1 (ru) Фармацевтическая композиция для применения в лечении фиброза
MX375934B (es) Composiciones farmaceuticas que comprenden agentes antibacterianos.
BR112016008704A8 (pt) derivados de indol-urea glucopiranosil-substituídos, composições farmacêuticas, e seus usos
KR101787247B9 (ko) 키토산-카페인산 유도체를 유효성분으로 하는 항균성 조성물
MX2013003022A (es) Composiciones farmaceuticas de montelukast y levocetirizina.
UA90602U (uk) Фармацевтична композиція комбінованої дії
GB201318635D0 (en) Preservative free pharmaceutical compositions for ophthalmic administration
TH1501001478A (th) องค์ประกอบทางเภสัชกรรมสำหรับการให้ทางปากซึ่งมีการละลาย และ/หรือ การดูดซึมดีขึ้น